Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: A potential cause of drug induced liver injury

Toxicological Sciences

Volumn 157, Issue 1, 2017, Pages 50-61

  Wolenski, Francis S ^a   X Zhu, Andy Z ^a   Johnson, Mike ^a,b   Yu, Shaoxia ^a   Moriya, Yuu ^a   Ebihara, Takuya ^a   Csizmadia, Vilmos ^a   Grieves, Jessica ^a   Paton, Martin ^a   Liao, Mingxiang ^a   Gemski, Christopher ^a   Pan, Liping ^a   Vakilynejad, Majid ^a   Dragan, Yvonne P ^a   Chowdhury, Swapan K ^a   Kirby, Patrick J ^a,c  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b Ignyta   (United States)

^c SANOFI   (France)

Author keywords

Bile acid inhibition; Biliary excretion; Biomarkers; Drug induced liver injury

Indexed keywords

ALPHA MURICHOLIC ACID; BETA MURICHOLIC ACID; BILE ACID; CHENODEOXYCHOLIC ACID; CHOLIC ACID; DEOXYCHOLIC ACID; FASIGLIFAM; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; GLYCODEOXYCHOLIC ACID; GLYCOLITHOCHOLIC ACID; GLYCOURSODEOXYCHOLIC ACID; HYODEOXYCHOLIC ACID; LITHOCHOLIC ACID; TAURO ALPHA MURICHOLIC ACID; TAURO BETA MURICHOLIC ACID; TAUROCHENODEOXYCHOLIC ACID; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; TAUROHYODEOXYCHOLIC ACID; TAUROLITHOCHOLIC ACID; TAUROURSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; BENZOFURAN DERIVATIVE; SULFONE; TAK-875;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID BLOOD LEVEL; CANINE MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; HOMEOSTASIS; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PATHOGENESIS; RAT; RAT MODEL; TOXIC HEPATITIS; ANIMAL; CELL CULTURE; DOG; DRUG EFFECTS; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BENZOFURANS; BILE ACIDS AND SALTS; CELLS, CULTURED; CHEMICAL AND DRUG INDUCED LIVER INJURY; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMEOSTASIS; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SULFONES;

EID: 85020110686     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfx018     Document Type: Article

References (47)

1. Aleo, M. D., Luo, Y., Swiss, R., Bonin, P. D., Potter, D. M., and Will, Y. (2014). Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 60, 1015-1022
2. Alrefai, W. A., and Gill, R. K. (2007). Bile acid transporters: Structure, function, regulation and pathophysiological implications. Pharm. Res. 24, 1803-1823
3. Attili, A. F., Angelico, M., Cantafora, A., Alvaro, D., and Capocaccia, L. (1986). Bile acid-induced liver toxicity: Relation to the hydrophobic-hydrophilic balance of bile acids. Med. Hypotheses 19, 57-69
4. Burant, C. F., Viswanathan, P., Marcinak, J., Cao, C., Vakilynejad, M., Xie, B., and Leifke, E. (2012). TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379, 1403-1411
5. Chiang, J. Y. (2009). Bile acids: Regulation of synthesis. J. Lipid Res. 50, 1955-1966
6. Chiang, J. Y. (2013). Bile acid metabolism and signaling. Compr. Physiol. 3, 1191-1212
7. Davies, B., and Morris, T. (1993). Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095
8. Dawson, P. A., Lan, T., and Rao, A. (2009). Bile acid transporters. J. Lipid Res. 50, 2340-2357
9. Dawson, S., Stahl, S., Paul, N., Barber, J., and Kenna, J. G. (2012). In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 40, 130-138
10. Farina, A., Dumonceau, J. M., and Lescuyer, P. (2009). Proteomic analysis of human bile and potential applications for cancer diagnosis. Expert Rev. Proteomics 6, 285-301
11. Fattinger, K., Funk, C., Pantze, M., Weber, C., Reichen, J., Stieger, B., and Meier, P. J. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69, 223-231
12. Halilbasic, E., Claudel, T., and Trauner, M. (2013). Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J. Hepatol. 58, 155-168
13. Hofmann, A. F. (2009). The enterohepatic circulation of bile acids in mammals: Form and functions. Front. Biosci. (Landmark Ed.) 14, 2584-2598
14. Jemnitz, K., Veres, Z., and Vereczkey, L. (2010). Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human. Toxicol. Sci. 115, 80-88
15. Kaku, K., Araki, T., and Yoshinaka, R. (2013). Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 36, 245-250
16. Kaku, K., Enya, K., Nakaya, R., Ohira, T., and Matsuno, R. (2015). Efficacy and safety of fasiglifam (TAK-875), a G proteincoupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: A randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes. Metab. 17, 675-681
17. Kaku, K., Enya, K., Nakaya, R., Ohira, T., and Matsuno, R. (2016). Long-term safety and efficacy of fasiglifam (TAK-875), a GPR40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: A 52-week open-label phase III study. Diabetes Obes. Metab. 18, 925-929
18. Kosters, A., and Karpen, S. J. (2008). Bile acid transporters in health and disease. Xenobiotica 38, 1043-1071
19. Kostrubsky, S. E., Strom, S. C., Kalgutkar, A. S., Kulkarni, S., Atherton, J., Mireles, R., Feng, B., Kubik, R., Hanson, J., Urda, E., et al. (2006). Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90, 451-459
20. Lam, P., Wang, R., and Ling, V. (2005). Bile acid transport in sister of P-glycoprotein (ABCB11) knockout mice. Biochemistry 44, 12598-12605
21. Lang, C., Meier, Y., Stieger, B., Beuers, U., Lang, T., Kerb, R., Kullak-Ublick, G. A., Meier, P. J., and Pauli-Magnus, C. (2007). Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with druginduced liver injury. Pharmacogenet. Genomics 17, 47-60
22. Legido-Quigley, C., McDermott, L., Vilca-Melendez, H., Murphy, G. M., Heaton, N., Lindon, J. C., Nicholson, J. K., and Holmes, E. (2011). Bile UPLC-MS fingerprinting and bile acid fluxes during human liver transplantation. Electrophoresis 32, 2063-2070
23. Leifke, E., Naik, H., Wu, J., Viswanathan, P., Demanno, D., Kipnes, M., and Vakilynejad, M. (2012). A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin. Pharmacol. Ther. 92, 29-39
24. Li, X., Zhong, K., Guo, Z., Zhong, D., and Chen, X. (2015). Fasiglifam (TAK-875) inhibits hepatobiliary transporters: A possible factor contributing to fasiglifam-induced liver injury. Drug Metab. Dispos. 43, 1751-1759
25. Marroquin, L. D., Hynes, J., Dykens, J. A., Jamieson, J. D., and Will, Y. (2007). Circumventing the Crabtree effect: Replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97, 539-547
26. Mayer, M., Nudurupati, S., Peng, X., and Marcinak, J. (2014). Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal function. Drugs R D 14, 273-282
27. Monte, M. J., Marin, J. J., Antelo, A., and Vazquez-Tato, J. (2009). Bile acids: Chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15, 804-816
28. Morgan, R. E., Trauner, M., van Staden, C. J., Lee, P. H., Ramachadran, B., Eschenberg, M., Afshari, C. A., Qualls, C. W., Lightfoot-Dunn, R., and Hamdeh, H. K. (2010). Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 118, 485-500
29. Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., 2nd, Afshari, C. A., and Hamadeh, H. K. (2013). A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol. Sci. 136, 216-241
30. Naik, H., Vakilynejad, M., Wu, J., Viswanathan, P., Dote, N., Higuchi, T., and Leifke, E. (2012). Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: Results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J. Clin. Pharmacol. 52, 1007-1016
31. Negoro, N., Sasaki, S., Mikami, S., Ito, M., Suzuki, M., Tsujihata, Y., Ito, R., Harada, A., Takeuchi, K., Suzuki, N., et al. (2010). Discovery of TAK-875: A potent, selective, and orally bioavailable GPR40 agonist. ACS Med. Chem. Lett. 1, 290-294
32. Nicolaou, M., Andress, E., Zolnericks, J. K., Dixon, P. H., Williamson, C., and Linton, K. J. (2012). Canalicular ABC transporters and liver disease. J. Pathol. 226, 300-315
33. Noe, J., Kullak-Ublick, G. A., Jochum, W., Stieger, B., Kerb, R., Haberl, M., Mullhaupt, B., Meier, P. J., and Pauli-Magnus, C. (2005). Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. J. Hepatol. 43, 536-543
34. Oshida, K., Shimamura, M., Seya, K., Ando, A., and Miyamoto, Y. (2016). Identification of transporters involved in beraprost sodium transport in vitro. Eur. J. Drug. Metab. Pharmacokinet. doi: 10.1007/s13318-016-0327-4
35. Ridlon, J. M., Kang, D. J., and Hylemon, P. B. (2006). Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241-259
36. Rodrigues, A. D., Lai, Y., Cvijic, M. E., Elkin, L. L., Zvyaga, T., and Soars, M. G. (2014). Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: Mechanistic considerations beyond the direct inhibition of the bile salt export pump. Drug Metab. Dispos. 42, 566-574
37. Russell, D. W. (2003). The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137-174
38. Stieger, B., Meier, Y., and Meier, P. J. (2007). The bile salt export pump. Pflugers Arch. 453, 611-620
39. Suzuki, Y., Kaneko, R., Nomura, M., Naito, H., Kitamori, K., Nakajima, T., Ogawa, T., Hattori, H., Seno, H., and Ishii, A. (2013). Simple and rapid quantitation of 21 bile acids in rat serum and liver by UPLC-MS-MS: Effect of high fat diet on glycine conjugates of rat bile acids. Nagoya J. Med. Sci. 75, 57-71
40. Swift, B., Pfeifer, N. D., and Brouwer, K. L. (2010). Sandwich-cultured hepatocytes: An in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab. Rev. 42, 446-471
41. Swiss, R., Niles, A., Cali, J. J., Nadanaciva, S., and Will, Y. (2013). Validation of a HTS-amenable assay to detect drug-induced mitochondrial toxicity in the absence and presence of cell death. Toxicol. In Vitro 27, 1789-1797
42. van Staden, C. J., Morgan, R. E., Ramachandran, B., Chen, Y., Lee, P. H., and Hamadeh, H. K. (2012). Membrane vesicle ABC transporter assays for drug safety assessment. Curr. Protoc. Toxicol. Chapter 23, Unit 23.5
43. Wang, R., Chen, H. L., Liu, L., Sheps, J. A., Phillips, M. J., and Ling, V. (2009). Compensatory role of P-glycoproteins in knockout mice lacking the bile salt export pump. Hepatology 50, 948-956
44. Wang, R., Salem, M., Yousef, I. M., Tuchweber, B., Lam, P., Childs, S. J., Helgason, C. D., Ackerley, C., Phillips, M. J., and Ling, V. (2001). Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc. Natl. Acad. Sci. U. S. A. 98, 2011-2016
45. Washizu, T., Ikenaga, H., Washizu, M., Ishida, T., Tomoda, I., and Kaneko, J. J. (1990). Bile acid composition of dog and cat gallbladder bile. Nihon Juigaku Zasshi 52, 423-425
46. Yang, K., Kock, K., Sedykh, A., Tropsha, A., and Brouwer, K. L. (2013). An updated review on drug-induced cholestasis: Mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J. Pharm. Sci. 102, 3037-3057
47. Zhang, Y. K., Guo, G. L., and Klaassen, C. D. (2011). Diurnal variations of mouse plasma and hepatic bile acid concentrations as well as expression of biosynthetic enzymes and transporters. PLoS One 6, e16683